31,384 Gilead Sciences, Inc. $GILD Shares Sold by CX Institutional

Key Points

• CX Institutional cut its Gilead Sciences stake by 53.8% in the third quarter, selling 31,384 shares and retaining 26,913 shares worth approximately $4.0 million. Institutional investors collectively own 83.67% of Gilead stock.
• Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year, driven largely by its HIV portfolio and Biktarvy. The company also pays a quarterly dividend of $0.82, equivalent to a 2.3% annualized yield.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and a $158.78 target price, although Zacks downgraded the stock to “hold.” Several insiders have also sold shares under pre-arranged Rule 10b5-1 trading plans.

CX Institutional decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 53.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,913 shares of the biopharmaceutical company's stock after selling 31,384 shares during the quarter. CX Institutional's holdings in Gilead Sciences were worth $4,011,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the stock. Aviva PLC grew its position in Gilead Sciences by 5.4% during the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company's stock valued at $141,978,000 after acquiring an additional 59,782 shares during the last quarter. Bank of Nova Scotia purchased a new position in Gilead Sciences in the 2nd quarter worth $100,056,000. OMERS ADMINISTRATION Corp bought a new stake in Gilead Sciences in the second quarter worth $55,754,000. Groupe la Francaise increased its holdings in shares of Gilead Sciences by 30.9% in the second quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company's stock worth $6,270,000 after buying an additional 11,712 shares during the period. Finally, Harvest Fund Management Co. Ltd lifted its stake in shares of Gilead Sciences by 14.4% in the 4th quarter. Harvest Fund Management Co. Ltd now owns 106,526 shares of the biopharmaceutical company's stock valued at $13,075,000 after acquiring an additional 13,385 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead’s HIV portfolio remains the primary growth driver. Biktarvy helped lift quarterly revenue to approximately $7.8 billion, while the company’s broader revenue increased 10.6% year over year. Biktarvy Drives Gilead Sciences Revenue to $7.8 Billion
• Positive Sentiment: Barron’s reiterated a bullish view, noting that Gilead shares have risen 35% since its earlier coverage but arguing that the company’s catalysts have not yet fully played out. The view supports continued investor interest in the pipeline and core HIV business. More Upside Awaits for Gilead Sciences Stock
• Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth about $2.2 million. Because the transaction was executed under a pre-arranged Rule 10b5-1 plan, it may have limited bearish significance, although insider selling can weigh on sentiment. Gilead SEC Form 4 Filing
• Neutral Sentiment: Gilead has become one of the most-watched stocks among Zacks users, indicating elevated market attention but not necessarily a change in fundamentals. Gilead Trending Stock Analysis
• Negative Sentiment: Zacks Research downgraded Gilead from “strong buy” to “hold,” potentially encouraging profit-taking after the stock’s strong recent advance and reducing near-term buying support.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $144.22, for a total value of $432,660.00. Following the sale, the insider owned 116,684 shares in the company, valued at $16,828,166.48. The trade was a 2.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the company's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director directly owned 12,894 shares in the company, valued at $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 105,000 shares of company stock valued at $14,940,540 in the last three months. 0.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Royal Bank Of Canada increased their target price on Gilead Sciences from $120.00 to $123.00 and gave the company a "sector perform" rating in a report on Wednesday, August 5th. Needham & Company LLC restated a "buy" rating and issued a $170.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Zacks Research cut shares of Gilead Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday. Barclays lowered their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 29th. Finally, Weiss Ratings raised Gilead Sciences from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, September 14th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $158.78.

Gilead Sciences Stock Down 1.9%

GILD stock opened at $144.74 on Friday. The stock has a market capitalization of $179.47 billion, a P/E ratio of -54.21 and a beta of 0.31. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences, Inc. has a 1-year low of $109.66 and a 1-year high of $157.29. The business has a fifty day moving average price of $143.63 and a 200-day moving average price of $136.55.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. During the same period last year, the firm earned $2.01 EPS. Gilead Sciences's revenue for the quarter was up 10.6% compared to the same quarter last year. Equities analysts forecast that Gilead Sciences, Inc. will post -0.48 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were issued a $0.82 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.3%. Gilead Sciences's dividend payout ratio is currently -122.85%.

About Gilead Sciences

Gilead Sciences, Inc NASDAQ: GILD is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead's portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.